First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting 200 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.

Timeline

Start: 2025-11-12
Primary completion: 2027-07
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	7MW4911	Unknown	—	Intravenous

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications